$1.91
+0.15(8.86%)
Mkt Cap $552M
$0.51
$5.18
52-Week Range
At A Glance
1
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.
2
Most recently: and Exhibit 99.1 is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or com (2026-02-02).
$552M
Market Cap
$4M
Revenue
-$336M
Net Income
Employees204
Fundamentals
How The Business Makes Money
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001850270
ISINUS74291D1046
CUSIP74291D104
Phone336 999 7028
Address2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, US
SEC EDGAR